IntraBio
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, IntraBio sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
IntraBio: 6 sponsored US clinical trials, 1 recruiting.
IntraBio sponsors 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. 3 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Ataxia-Telangiectasia, with 2 trials.
Upper-quartile sponsor footprint
IntraBio sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C
NCT05163288
A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)
NCT06673056
N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)
NCT03759678
Pivotal Study of N-acetyl-L-leucine for CACNA1A
NCT07221292
N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)
NCT03759639
N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease)
NCT03759665
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 3 | 3 |
Therapeutic Areas
What is open in the IntraBio pipeline
1 recruiting of 6 indexed (17% open); 2 completed (33%).
Phase mix: 3 late (III/IV) vs 3 early (I/II) (balanced across stages).
Top condition: Ataxia-Telangiectasia (2 trials), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
IntraBio: open-pipeline peers nationwide
Peers matched on 6 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
IntraBio sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Angiodynamics · 17% recruiting · 12 trials
Related
What to do with this IntraBio page
6 registered trials is a research-attention snapshot, not an endorsement of IntraBio or any single study.
- 1 of IntraBio's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Ataxia-Telangiectasia is the condition IntraBio studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Ataxia-Telangiectasia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
IntraBio pipeline card: 6 registered trials from official public datasets.Report a data error.